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Several genome-wide association studies (GWASs) have identified numerous susceptibility genes for risk of rheumatoid 
arthritis (RA). Moreover, a bulk of the individual association studies in various populations has disclosed that genetics are 
significantly responsible for RA pathogenesis. CCR6 is a chemokine which is involved in the infiltration of inflammatory 
cells to sites of immune response. In this study, the association of CCR6 gene rs1854853 single nucleotide polymorphism 
(SNP) with susceptibility to RA was evaluated in an Iranian population. The investigated population comprised 250 RA 
patients and 500 healthy individuals. Real time TaqMan MGB-based PCR allelic discrimination approach was employed to 
genotype the samples with regard to the CCR6 gene rs1854853 SNP. Considering the A allele of rs1854853 SNP as 
reference, the G allele did not demonstrate a different prevalence between RA patients and controls (p= 0.17). Moreover, 
AG and GG genotypes were almost equally distributed between cases and controls (p= 0.61 and 0.14, respectively). 
Alternately, the dominant model of AG+GG had no significant difference in frequency between the study groups (p= 0.36). 
However, genotypes did show a correlation with the clinicopathological specifications of RA patients. Results suggest that 
the CCR6 gene rs1854853 SNP is not involved in the genetic pathogenesis of RA in the Iranian population. 
Keywords: CCR6 gene, rheumatoid arthritis, single nucleotide polymorphism. 
Introduction __________________________  
Rheumatoid Arthritis (RA) is an obvious example of a 
disease encompassing definite features of 
rheumatologic manifestations with the signs of pain, 
swelling, and tenderness of joints which are caused by 
a mixture of autoimmune, genetic, and environmental 
factors [1, 2]. RA is characterized by synovium over-
proliferation, cytokine and chemokine overproduction, 
autoantibodies such as anti-cyclic citrullinated peptide 
antibody (Anti-CCP) and rheumatoid factor (RF), 
angiogenesis, osteoclastogenesis, and cardiovascular 
and pulmonary complications [3]. In RA, several 
immune cells such as plasma cells, macrophages, 
dendritic cells (DCs), and lymphocytes as well as 
immune complexes infiltrate the synovium 
environment. Fibroblast-like synoviocytes in RA 
release various mediators like chemokines, cytokines, 
and matrix metalloproteinases (MMPs), which degrade 
the extracellular matrix and eradicate the articular 
structures in joints [4, 5]. 
To the best of the authors‘ knowledge and based on 
numerous studies performed in recent years, 
autoimmune responses along with genetic materials are 
the main culprits to be blamed for causing such 
diseases [6-9]. Genome-wide association studies 
(GWASs) have clarified new loci or genes that are 
linked to RA. In this regard, the more new genetic 
causalities are discovered, the more beneficial new 
approaches to cure the diseases can be found [10].  
As a subset of CD4+ T helper (Th) cells, IL-17-
producing Th17 cells express CCR6 (CC chemokine 
receptor 6) on themselves, which is bound to its ligand 
(CCL20), eventuating in the homing of these cells to 
inflamed joints. By producing IL-17, a well-known 
inflammatory cytokine in most autoimmune diseases, 
Th17 cells play an important role in the pathogenesis 
of RA [11]. According to studies conducted on RA, 
some important risk alleles which impact the immune 
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system have been revealed [12]. CCR6 gene 
polymorphisms have been implicated in RA 
susceptibility [13, 14]. In addition to RA, CCR6 gene 
SNPs have been associated with Crohn's disease, 
colorectal cancer, Graves‘ disease, and psoriasis [15-
17]. Various SNPs in this gene, including rs3093024, 
rs3099023, and rs1854853, have been surveyed during 
recent years, especially in European, Southeast Asian, 
and African-American populations [18]. A meta-
analysis indicated that the CCR6 gene rs1854853 SNP 
was associated with an increased risk of RA in 
different populations [18]. Moreover, a GWAS 
reported the strong association of rs1854853 with the 
risk of RA in Han Chinese and European white 
populations as well as with the clinical outcomes of the 
disease [13]. 
Considering the important role of CCR6 in the 
immunopathogenesis of RA and previously-observed 
strong association of CCR6 gene polymorphisms, 
particularly rs1854853, with the risk of RA, the current 
study evaluated the effect of this SNP on the risk of 
RA in an Iranian population. Furthermore, the 
association of genotypes of rs1854853 SNP with the 
clinical specifications of RA patients was analyzed. 
Materials and Methods _________________  
Patients and Controls 
From a total of 750 individuals, 250 RA patients (49 
males and 201 females) who met 2010 American 
College of Rheumatology (ACR) classification criteria 
[19] and 500 healthy controls (113 males and 387 
females) were recruited from the Outpatient 
Rheumatology Clinic of Shariati Hospital. None of the 
healthy control subjects  had autoimmune or rheumatic 
diseases either in themselves or among their family 
members. The two groups were matched in terms of 
age, gender, and ethnicity. The mean age of patients 
was 50.91±12.60 and of controls was 42.49±12.97 
years. All participants completed informed consent 
forms with total satisfaction. The study was approved 
by the Ethics Committee of Tehran University of 
Medical Sciences. To perform the experiments, 5 ml of 
peripheral blood was collected from each individual in 
EDTA-anticoagulated tubes and ESR blood collection 
test tubes using venipuncture. 
Genotyping  
Genomic DNA was extracted from peripheral blood 
using the phenol-chloroform method [20]. TaqMan 
MGB-based allelic discrimination technique was 
employed to genotype the subjects. PCR reaction 
mixture contained 4.5 μl of genomic DNA, 5 μl Taq-
Man Master Mix containing Taq DNA polymerase and 
dNTPs (Applied Biosystems, Foster City, USA), 
0.25μl Taq-Man Genotyping Assay mix containing 
primers and FAM or VIC labeled probes (Applied 
Biosystems, Foster City, USA), and distilled water for 
a final volume of 10 μl. Thermocyclic conditions of 
PCR were initially 60 °C for 30 seconds, then 95 °C 
for 10 mins, subsequently 40 cycles of amplification 
(95 °C for 15 seconds and 60 °C for 1 min), and finally 
60 °C for 30 seconds. 
Statistical analysis 
The chi-square test was utilized to analyze the 
polymorphism association with the disease. Odds ratio 
(OR) as the effect size with 95% confidence intervals 
(95% CI) were measured. Allele frequency and 
genotype distribution in the control group were 
evaluated to assess deviations from Hardy-Weinberg 
equilibrium (HWE). The association of clinical 
manifestations with the genotypes was also verified 
applying analysis of variance (ANOVA) using SPSS 
version 22 (SPSS Inc., Chicago, IL, USA). A p< 0.05 
was considered as statistically significant. 
Results _______________________________  
Table 1 shows the demographic features and laboratory 
findings of RA patients and healthy control groups. 
Autoantibodies, including RF and Anti-CCP, were 
positive in 175 (70.1%) and 160 (64%) RA patients, 
respectively. Deformity of the joints was seen in 45 
(18%) patients. Moreover, morning stiffness and 
arthritis were observed in 120 (48%) and 140 (56%) 
patients, respectively. Measured values for the disease 
activity score-28 (DAS28), erythrocyte sedimentation 
rate (ESR), patient global assessment (PGA), visual 
analog scale (VAS), tender joint counts-28 (TJC28), 
and swollen joint counts-28 (SJC28) are shown in 
Table 1. 
No significant deviation from the HWE (p= 0.84) 
was observed in the genotype distribution of the CCR6 
gene rs1854853 SNP in the healthy control population 
(Table 2). 
The global major allele of A was assigned as the 
reference allele for rs1854853 SNP according to the 
NCBI database (https://www.ncbi.nlm.nih.gov/projects/SNP/). 
The frequency of the G allele for rs1854853 SNP was 
less in RA patients than controls (41.2% vs. 45.6%, 
respectively); however, the difference was not 
significant (OR= 0.84, CI: 0.65-1.08; p= 0.17). On the 
other side, the AA genotype was considered as the 
reference. The difference in the AG genotype 
frequencies was not significant between patient and 
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control groups (OR= 0.90, CI: 0.60-1.35; p= 0.61). 
 
Table 1. Demographic data and laboratory specifications of rheumatoid arthritis patients and healthy controls 
Characteristic RA patients N=250 (%) Healthy individuals N=500 (%) 
Male 49 (19.6%) 
+
 113 (22.6%) 
Female 201 (80.4%)
+
 387 (77.4%) 
Age 50.91±12.605* 42.49±12.971 
Smoker 3 (1.2%)
+
 42 (8.4%) 
RF (positive) 175 (70.1%)
+
 - 
Anti-CCP (positive) 160 (64%)
+
 - 
DAS28 3.33±1.212* - 
ESR 19.87±17.10* - 
Deformity (positive) 45 (18%)
+
 - 
Morning stiffness (positive) 120 (48%)
+
 - 
Arthritis (positive)  140 (56%)
+
 - 
PGA 28.27±11.97* - 
VAS 28.18±11.87* - 
TJC28 2.89±3.42* - 
SJC28 2.13±3.18* - 
RA, Rheumatoid Arthritis; RF, Rheumatoid Factor; Anti-CCP, Anti-Cyclic Citrullinated Peptide Antibody; DAS28, Disease Activity 
Score for 28 Joints; ESR, Erythrocyte Sedimentation Rate, PGA, Patient global assessment; VAS, Visual Analogue Scale; TJC, 
Tender joint count; SJC, Swollen joint count. 
* Data are presented as Mean ± Standard Deviation; 
+ 
Data are presented as N (%). 
 
Table 2. Allele and genotype distribution of CCR6 rs1854853 SNP in RA patients and healthy controls  





OR (95% CI) p value 
rs1854853 
A 294 (58.8%) 544 (54.4%) Reference - 
G 206 (41.2%) 456 (45.6%) 0.836 (0.647-1.081) 0.17 
AA 82 (32.8%) 143 (28.6%) Reference - 
AG 130 (52%) 256 (51.2%) 0.90 (0.598-1.353) 0.61 
GG 38 (15.2%) 101 (20.2%) 0.66 (0.387-1.146) 0.14 
AG+GG 168 (67.2%) 357 (71.4%) 0.834 (0.565-1.230) 0.36 
HWE  - p= 0.84   
RA, Rheumatoid Arthritis; HWE, Hardy–Weinberg Equilibrium  
 
Although the GG genotype was less frequent in RA 
patients than controls (15.2% vs. 20.2%, respectively), 
the difference was not statistically significant (OR= 
0.66, CI: 0.39-1.15; p = 0.14). The AG+GG pattern 
was the dominant genotype, and it was represented 
more frequently in controls than in RA patients (71.4% 
vs. 67.2%, respectively); nonetheless, the distribution 
difference was not significant (OR= 0.83, CI: 0.56-
1.23; p = 0.36). 
The association of clinical manifestations of RA 
patients according to genotypes of CCR6 gene 
rs1854853 revealed that the clinical values were not 
related to variations in genotypes (Table 3). The 
clinical items were RF, Anti-CCP, DAS28, ESR, 
deformity of joints, morning stiffness, arthritis, PGA, 
VAS, TJC28, and SJC28, and none of them were 
associated with rs1854853 GG, AG, or AA genotypes. 
Discussion ____________________________  
The role of genetics in the onset or development of 
various types of disease, including autoimmune ones, 
has been one of the most controversial issues discussed 
in recently written articles. Researchers all over the 
world search for probable causal pathogenesis 
mechanisms in RA. Numerous studies have uncovered 
new loci in HLA or outside HLA regions that are 
CCR6 polymorphism and RA 
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highly related to RA susceptibility, progression, or 
response to drugs such as disease-modifying 
antirheumatic drugs (DMARDs) [6, 21]. 
Table 3. Association of CCR6 gene rs1854853 genotypes with various clinical features of the 250 RA patients 
Characteristic GG AG AA p value 
RF* 63 (36.8%) 68 (39.1%) 53 (30.5%) 0.613 
Anti-CCP* 19 (50%) 77 (59.2%) 64 (78%) 0.293 
DAS28 3.43 ± 1.25 3.22 ± 1.13 3.45 ± 1.31 0.409 
ESR 23.62 ± 24.59 18.33 ± 14.21 20.56 ± 17.08 0.282 
Deformity* 4 (10.5%) 30 (23%) 12 (14.6%) 0.146 
Morning stiffness* 23 (60.5%) 59 (45.4%) 44 (53.6%) 0.365 
Arthritis* 22 (57.9%) 66 (50.7%) 52 (63.4%) 0.241 
PGA 28.1 3± 9.98 28.05 ± 12.19 28.70 ± 12.22 0.937 
VAS 27.50 ± 9.837 28.23 ± 12.07 28.41 ± 12.55 0.936 
TJC28 3.41 ± 3.38 2.60 ± 2.89 3.10 ± 4.14 0.412 
SJC28 1.84 ± 2.23 2.04 ± 3.18 2.42 ± 3.55 0.631 
RA, Rheumatoid Arthritis; RF, Rheumatoid Factor; Anti-CCP, Anti-Cyclic Citrullinated Peptide Antibody; DAS28, Disease Activity 
Score for 28 Joints; ESR, Erythrocyte Sedimentation Rate, PGA, Patient global assessment; VAS, Visual Analogue Scale; TJC, 
Tender joint count; SJC, Swollen joint count.  
*
Data are presented as number of positive (%); 
+ 
Data are presented as number (%) in each cell.
RA is depicted as an autoimmune disease with 
systemic inflammation which specifically manifests as 
joint destruction and partial involvement of other 
organs [1]. Most patients experience intense 
inflammation with exacerbated health conditions over 
time, showing physical incapacitation and an over-
representation of the mortality rate compared to the 
general population [3, 22-24]. Autoantibodies 
alongside cellular immunity (including CD4+ T cells 
and related pro-inflammatory cytokines) which are 
prerequisites for progression of the disease constitute 
the main players of autoimmune diseases such as RA 
[3]. Based on recent studies, Th17 cells play a crucial 
role in RA progression by homing in on inflamed joints 
and mediating degradation of cartilage. The 
recruitment of Th17 cells to involved tissues occurs 
when CCR6 as a cell surface molecule is attached to its 
ligand, CCL20, which is produced in the synovial cells 
of RA patients [25]. CCR6 is also expressed on DCs, 
subsets of B Cells, and γδT cells which produce IL-17, 
contributing to the inflammation [14].  
GWASs and studies of other associations have 
identified CCR6 gene polymorphisms as a risk factor 
for RA predisposition. These studies have investigated 
populations with different ethnic backgrounds, 
however they represent contradictory results. Although 
most of them identified a significant relationship 
between polymorphisms and disease proneness, others 
did not observe any association [18]. The CCR6 gene 
rs1854853 association was first discovered in a study 
on a Han Chinese population [13], as the G allele of 
this polymorphism was associated with the decreased 
risk of RA. Moreover, genotypes rs1854853 depicted a 
strong association with Anti-CCP-positive, but not 
with Anti-CCP-negative RA patients [13].  
Based on our analysis, the current results are not in 
accord with some previous studies, and no significant 
association between CCR6 gene rs1854853 
polymorphism and RA risk in the Iranian population 
was observed. The inconsistency observed in gene 
association studies can be attributed to several issues. 
The first and most important one is deemed to be the 
racial or ethnic disparity between Iranians and other 
descents, explaining genetic heterogeneity. Another 
factor that should be considered is the difference in 
sample sizes among different studies. 
In addition to the positive points of this study, such 
as the fairly large sample size and matching the case 
and controls with respect to ethnicity to eliminate 
population stratification bias, there were a number of 
limitations and caveats. The CCR6 gene has been 
studied for a number of SNPs in autoimmune diseases. 
However, this study evaluated only one of them, and 
that may result in the omission of the concept of 
interactions between positions which function in an 
expanded network to cause RA. Moreover, the genetic 
SNPs of other genes in conjunction with the CCR6 
gene as regards immunological functions were not 
investigated. 
Overall, this study investigated the association 
between the CCR6 gene rs1854853 SNP and a 
predisposition to RA. No association was found 
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between alleles or genotypes of rs1854853 and RA 
risk. Furthermore, no association was observed 
between clinical features of RA patients and genotypes 
of rs1854853 SNP. It seems that the evaluation of this 
polymorphism in different ethnicities through 
comprehensive studies like meta-analyses will help 
researchers achieve a more valid understanding about 
the role of CCR6. 
Acknowledgments 
Those patients who made the accomplishment of this 
study a reality are kindly acknowledged. This study 
was underwritten by a financial grant from the 
Research Deputy of Tehran University of Medical 
Sciences (Grant No. 96-02-30-325643). 
Conflicts of interest 
The author declares no conflicts of interest. 
References ______________________________________________________________________ 
1. Sandoughi M, Kaykhaei MA, 
Shahrakipoor M, Darvishzadeh 
R, Nikbakht M, Shahbakhsh S. 
et al. Clinical manifestations 
and disease activity score of 
rheumatoid arthritis in southeast 
of Iran. Rheumatology 
Research 2017; 2(2): 61-64. 
doi: 10.22631/rr.2017.69997. 
1019. 
2. Mahmoudi M, Aslani S, Fadaei




of Rheumatic Diseases 2017;
20(3): 289-97. doi:
10.1111/1756-185x.12999.
3. McInnes IB, Schett G. The
pathogenesis of rheumatoid
arthritis. New England Journal
of Medicine 2011; 365(23):
2205-19. doi: 10.1056/nejmra
1004965.
4. Firestein GS. Evolving concepts
of rheumatoid arthritis. Nature
2003; 423(6937): 356-61. doi:
10.1038/nature01661.
5. Bradfield PF, Amft N, Vernon‐
Wilson E, Exley AE, Parsonage
G, Rainger G. et al. Rheumatoid
fibroblast‐like synoviocytes 
overexpress the chemokine 
stromal cell–derived factor 1 
(CXCL12), which supports 
distinct patterns and rates of 
CD4+ and CD8+ T cell 
migration within synovial tissue. 
Arthritis & Rheumatology 
2003; 48(9): 2472-82. doi: 
10.1002/art.11219. 
6. Kurkó J, Besenyei T, Laki J,
Glant TT, Mikecz K, Szekanecz
Z. Genetics of rheumatoid
arthritis—a comprehensive
review. Clinical reviews in
allergy & immunology 2013;
45(2): 170-79. doi: 10.1007/
s12016-012-8346-7. 
7. AR J. PADI4 polymorphisms in
Iranian patients with rheumatoid
arthritis. Acta reumatologica
portuguesa 2016; 41(4).
8. Nazari M, Mahmoudi M,
Rahmani F, Akhlaghi M, Beigy
M, Azarian M. et al. Association
of killer cell immunoglobulin-
like receptor genes in iranian
patients with rheumatoid
arthritis. PloS one 2015; 10(12):
e0143757. doi: 10.1371/journal.
pone.0143757.
9. Malekshahi Z, Mahmoudi M,
Akhlaghi M, Garshasbi M,
Jamshidi AR, Nicknam MH.
Lack of association between btb
domain and cnc homolog 2
polymorphism and susceptibility
to rheumatoid arthritis in Iranian
population. Indian Journal of
Rheumatology 2016; 11(4):197.
doi: 10.4103/0973-3698.192682.
10. Prasad P, Kumar A, Gupta R,
Juyal RC, Thelma B. Caucasian
and Asian specific rheumatoid
arthritis risk loci reveal limited
replication and apparent allelic
heterogeneity in north Indians.
PloS one 2012; 7(2): e31584.
doi: 10.1371/journal.pone.
0031584.
11. Hirota K, Yoshitomi H, 
Hashimoto M, Maeda S, 
Teradaira S, Sugimoto N. et al. 
Preferential recruitment of 
CCR6-expressing Th17 cells to 
inflamed joints via CCL20 in 
rheumatoid arthritis and its 
animal model. The Journal of 
Experimental Medicine 2007; 
204(12): 2803-12. doi: 10.1084/ 
jem.20071397. 
12. Messemaker TC, Huizinga TW,
Kurreeman F. Immunogenetics
of rheumatoid arthritis: 
understanding functional 
implications. Journal of 
autoimmunity 2015; 64: 74-81. 
doi: 10.1016/j.jaut.2015.07.007. 
13. Jiang L, Yin J, Ye L, Yang J,
Hemani G, Liu AJ. et al. Novel
risk loci for rheumatoid arthritis
in Han Chinese and congruence
with risk variants in Europeans.
Arthritis & rheumatology 2014;
66(5): 1121-32. doi: 10.1002/
art.38353.
14. Kochi Y, Okada Y, Suzuki A,
Ikari K, Terao C, Takahashi A.
et al. A regulatory variant in
CCR6 is associated with 
rheumatoid arthritis 
susceptibility. Nature genetics 
2010; 42(6): 515-19. doi: 10. 
1038/ng.583. 
15. Wang K, Zhang H, Kugathasan
S, Annese V, Bradfield JP,
Russell RK. et al. Diverse
genome-wide association studies
associate the IL12/IL23 pathway
with Crohn Disease. The
American Journal of Human
Genetics 2009; 84(3): 399-405.
doi: 10.1016/j.ajhg.2009.01.026.
16. Rubie C, Kruse B, Frick VO,
Kölsch K, Ghadjar P, Wagner
M. et al. Chemokine receptor
CCR6 expression is regulated by
miR-518a-5p in colorectal 
cancer cells. Journal of 
translational medicine 2014; 
12(1): 48. doi: 10.1186/1479-
5876-12-48. 
17. Perkins EA, Landis D, Causey
ZL, Edberg Y, Reynolds RJ,
Hughes LB. et al. Association of
single‐nucleotide
polymorphisms in CCR6,
TAGAP, and TNFAIP3 with
rheumatoid arthritis in African
Americans. Arthritis &
Rheumatism 2012; 64(5): 1355-
58. doi: 10.1002/art.33464.
18. Cheng P, Zhang Y, Huang H,
CCR6 polymorphism and RA 
40 Rheum. Res., Vol. 3, No. 1, Jan. 2018 
Zhang W, Yang Q, Guo F. et al. 
Association between CCR6 and 
rheumatoid arthritis: a meta-
analysis. International Journal 
of Clinical & Experimental 
Medicine 2015; 8(4):5388. 
19. Aletaha D, Neogi T, Silman AJ,
Funovits J, Felson DT, Bingham
CO. et al. Rheumatoid arthritis
classification criteria: an 
American College of 
Rheumatology/ European 
League Against Rheumatism 
collaborative initiative. Arthritis 
& Rheumatism 2010; 62(9): 
2569-81. 
20. Roe BA, Crabtree JS, Khan AS.
DNA isolation and sequencing.
John Wiley & Sons; 1996.
21. Yamamoto K, Okada Y, Suzuki
A, Kochi Y. Genetics of
rheumatoid arthritis in Asia
[mdash] present and future.
Nature Reviews Rheumatology 
2015; 11(6): 375-79. doi: 
10.1038/nrrheum.2015.7. 
22. Choy E. Understanding the
dynamics: pathways involved in
the pathogenesis of rheumatoid
arthritis. Rheumatology 2012;
51(suppl 5): v3-v11. doi:
10.1093/rheumatology/kes113.
23. Ahmadi H, Jamshidi A,
Mahmoudi M, Cuzzocrea S,
Fattahi M, Barati A. et al. The
potent inhibitory effect of β-D-





and anti-dsDNA antibodies in
patients with rheumatoid
arthritis. Current drug discovery
technologies 2017; 14(3). doi:
10.2174/1570163814666170321
113059. 
24. Mobini M, Mohammadpour RA,
Tahmasbi B, Karimi T. Cost




Research 2017; 2(2): 65-70.
doi: 10.22631/rr.2017.69997.
1020.
25. Hirota K, Yoshitomi H, 
Hashimoto M, Maeda S, 
Teradaira S, Sugimoto N. et al. 
Preferential recruitment of 
CCR6-expressing Th17 cells to 
inflamed joints via CCL20 in 
rheumatoid arthritis and its 
animal model. Journal of 
Experimental Medicine 2007; 
204(12): 2803-12. doi: 10.1084/ 
jem.20071397.
